Oncogenes articles within Nature Communications

Featured

  • Article
    | Open Access

    Mutations in the Protein Phosphatase PPM1D are oncogenic in certain cancers including diffuse intrinsic pontine glioma (DIPG). Here, the authors show that PPM1D mutations in DIPG induce the silencing of the nicotinic acid phosphoribosyltransferase gene and display synthetic lethality with nicotinamide phosphoribosyltransferase inhibitors.

    • Nathan R. Fons
    • , Ranjini K. Sundaram
    •  & Ranjit S. Bindra

  • Article
    | Open Access

    Multi-omic profiling is a powerful approach to dissecting molecular mechanisms in disease. Here the authors generate whole proteome, phosphoproteome and transcriptome profiles from two mouse models of high-grade glioma driven by different oncogenes, and validate identified master regulators with a CRISPR screen.

    • Hong Wang
    • , Alexander K. Diaz
    •  & Junmin Peng

  • Article
    | Open Access

    The expression of oncogenic MYC paralogs in small cell lung cancer is mutually exclusive. In this study, the authors show that MYC, but not MYCN or MYCL, represses BCL2, resulting in cells that are uniquely sensitive to apoptosis, and find that CHK1 and AURKA inhibitors may be useful for treating these cancers.

    • Marcel A. Dammert
    • , Johannes Brägelmann
    •  & Martin L. Sos

  • Article
    | Open Access

    Non alcoholic fatty liver disease (NAFLD) associates with an elevated risk of developing hepatocellular carcinoma (HCC). Here, the authors find that Nogo-B, an endoplasmic reticulum resident protein, is upregulated by lipid uptake and acts as an oncogene in NAFLD-associated HCC by promoting lipid droplet breakdown by lipophagy and triggering Hippo pathway dysregulation

    • Yuan Tian
    • , Bin Yang
    •  & Pengyuan Yang

  • Article
    | Open Access

    KRASG12V and BRAFV600E are oncogenic mutations that activate ERK signalling. Here, the authors use single cell analysis in intestinal organoids and show that BRAFV600E activates ERK in all intestinal cell types, while KRASG12V induces ERK activation in only a subset of cells, depending on cell differentiation state.

    • Raphael Brandt
    • , Thomas Sell
    •  & Markus Morkel

  • Article
    | Open Access

    Polycomb Repressor Complex 2 (PRC2) is frequently up-regulated in cancers. Here, the authors show that the tyrosine kinase c-Src stimulates mitochondrial function to signal energy sufficiency to mTORC1, increasing translation of the PRC2 subunits EZH2 and SUZ12 to support ErbB2-dependent tumours.

    • Harvey W. Smith
    • , Alison Hirukawa
    •  & William J. Muller

  • Article
    | Open Access

    LNK is a tumor suppressor in hematopoietic cancers, but its function in melanoma is unclear. Here, the authors show that the overexpression of LNK in melanomas correlate with hyperactive signaling of the RAS-RAF-MEK pathway and LNK enhances melanoma growth and survival and immune evasion by inhibiting IFN signalling.

    • Ling-Wen Ding
    • , Qiao-Yang Sun
    •  & H. Phillip Koeffler

  • Article
    | Open Access

    Hyperactivation of Akt promotes tumorigenesis. Here, the authors show that SAV1, a member of Hippo signalling, interacts with Akt to suppress Akt activity and MERTK-mediated Akt phosphorylation relieves this suppression to facilitate Akt oncogenic activity in clear cell renal carcinomas.

    • Yao Jiang
    • , Yanqiong Zhang
    •  & Pengda Liu

  • Article
    | Open Access

    Curaxins are a recently discovered class of anti-cancer agents that disturbs DNA/histone interactions within. Here the authors provide evidence that curaxins affect the spatial genome organization and compromise enhancer-promoter communication necessary for expression of several oncogenes, including MYC.

    • Omar L. Kantidze
    • , Artem V. Luzhin
    •  & Sergey V. Razin

  • Article
    | Open Access

    Oncogene-induced replication stress (RS) promotes cancer development. Here, the authors report that cancer cells adapt to oncogene-induced RS by overexpressing downstream components of ATR-CHK1 pathway, Claspin and Timeless, which have protective role at the replication forks independent of their checkpoint function.

    • Julien N. Bianco
    • , Valérie Bergoglio
    •  & Philippe Pasero

  • Article
    | Open Access

    Focal amplifications are prevalent in many cancer genomes. Here, the authors present AmpliconArchitect (AA), a computational tool for reconstructing their architecture, and reveal an extrachromosomal origin for focal amplifications, including hybrid human-virus elements in HPV-mediated cancers.

    • Viraj Deshpande
    • , Jens Luebeck
    •  & Vineet Bafna

  • Article
    | Open Access

    Medulloblastoma is one of the most prevalent malignant brain tumors in children and has very poor prognosis. In this study, the authors show, using a mouse model of medulloblastoma, that Gfi1 promotes tumor growth by recruiting Lsd1, that this interaction inhibits genes involved in neuronal differentiation, and that Lsd1 may be a therapeutic target in Gfi1-activated tumors.

    • Catherine Lee
    • , Vasilisa A. Rudneva
    •  & Robert J. Wechsler-Reya

  • Article
    | Open Access

    Overexpression of RAS proteins is frequently observed in patients with hepatocellular carcinoma. Here, the authors identify an HRAS binding protein, the E3 ubiquitin ligase WDR76, which promotes HRAS degradation, thus functioning as a tumour suppressor in liver cancer

    • Woo-Jeong Jeong
    • , Jong-Chan Park
    •  & Kang-Yell Choi

  • Article
    | Open Access

    In gene regulation, diversification at the transcriptome 3′end is linked to differentiation and dedifferentiation. Here, the authors discover extensive transcriptome 3′end-alterations in neuroblastoma, regulated by PCF11, and provide an interactive data repository of transcriptome-wide alternative polyadenylation.

    • Anton Ogorodnikov
    • , Michal Levin
    •  & Sven Danckwardt

  • Article
    | Open Access

    Pancreatic ductal adenocarcinoma (PDAC) cells display varying degrees of reliance on oncogenic KRAS. Here the authors show that KRAS-resistant PDAC cells maintain nucleotides synthesis through a KRAS-independent upregulation of the non-oxidative pentose phosphate pathway gene RPIA and that targeting nucleotide metabolism restore sensitivity to KRAS pathway inhibition.

    • Naiara Santana-Codina
    • , Anjali A. Roeth
    •  & Alec C. Kimmelman

  • Article
    | Open Access

    The role of protein arginine methyltransferases (PRMTs) in epigenetic regulation in cancer is still poorly understood. Here, the authors show that PRMT2 is highly expressed in Glioblastoma multiforme (GBM) and provide evidence that PRMT2 acts as a transcriptional co-activator for oncogenic gene expression programs, at least partly dependent on its H3R8me2a activity, in GBM pathogenesis.

    • Feng Dong
    • , Qian Li
    •  & Xudong Wu

  • Article
    | Open Access

    T-acute lymphoblastic leukemia is an aggressive cancer. Here the authors provide insights into the functional role of SHQ1, an H/ACA snoRNP assembly factor involved in snRNA pseudouridylation, in T-lymphoblastic leukemia cell survival through regulating the maturation of MYC mRNA.

    • Hexiu Su
    • , Juncheng Hu
    •  & Hudan Liu

  • Article
    | Open Access

    Chr3q26 rearrangements cause overexpression of EVI1 and associate with myeloid neoplasms, but the mechanism behind this association is unclear. Here, using a novel mouse model they show that EVI1 causes premalignant myeloid expansion with suppression of other lineages through upregulation of Spi1/PU.1.

    • Edward Ayoub
    • , Michael P. Wilson
    •  & Archibald S. Perkins

  • Article
    | Open Access

    Master regulator transcription factors TP63 and SOX2 have been reported to overlap in genomic occupancy in squamous cell carcinomas (SCCs). Here, the authors demonstrate that TP63 and SOX2 promote co-operatively long non-coding RNA CCAT1 expression through activating its super-enhancer, and CCAT1 forms a complex with TP63 and SOX2, which regulates EGFR super-enhancers and enhances both the MEK/ERK1/2 and PI3K/AKT signaling pathways in SCC.

    • Yuan Jiang
    • , Yan-Yi Jiang
    •  & H. Phillip Koeffler

  • Article
    | Open Access

    The Hippo pathway is frequently dysregulated in cancer. Here, the authors identify NUAK2 as negative regulator of the Hippo pathway from a siRNA kinome screen and show that NUAK2 promotes YAP/TAZ nuclear localisation while NUAK2 is a transcriptional target of YAP/TAZ, thus providing a feed forward loop to promote tumorigenesis.

    • Mandeep K. Gill
    • , Tania Christova
    •  & Liliana Attisano

  • Article
    | Open Access

    Little is known about the contribution of germline genetic variants to cancer drug sensitivity. Here, the authors devise an approach for joint analysis of germline variants and somatic mutations, identifying substantial germline contributions to variation in drug sensitivity.

    • Michael P. Menden
    • , Francesco Paolo Casale
    •  & Oliver Stegle

  • Article
    | Open Access

    Polycomb group protein EZH2 is overexpressed in ER- breast cancer, promoting metastasis. Here, the authors show that independent of the polycomb group, phosphorylation of EZH2 at T367 by p38 promotes cytoplasmic localization of EZH2, binding to vinculin and other regulators of cell migration and invasion.

    • Talha Anwar
    • , Caroline Arellano-Garcia
    •  & Celina G. Kleer

  • Article
    | Open Access

    Chordoid glioma is a slow growing diencephalic tumor whose mutational landscape is poorly characterized. Here, the authors perform whole-exome and RNA-sequencing and find that 15 of 16 chordoid glioma cases studied harbor the same PRKCA mutation which results in enhanced proliferation.

    • Shai Rosenberg
    • , Iva Simeonova
    •  & Marc Sanson

  • Article
    | Open Access

    Hippo and Wnt pathways are important for cancer development, and they can cross talk; however, the mechanisms behind this connection are unknown. Here the authors show that DVL (a scaffold protein in the Wnt pathway) regulates the shuttling of YAP (a key component of the Hippo pathway) between cytoplasm and nucleus in specific tumor suppressor contexts.

    • Yoonmi Lee
    • , Nam Hee Kim
    •  & Jong In Yook

  • Article
    | Open Access

    Long intergenic non-coding RNAs have been linked to cancer development. Here the authors, using RNA-seq and genomic amplification data, identify lincRNAs deregulated in hepatocellular carcinoma and propose that Linc01138 is stabilized by IGF2BP1/3 in the cytoplasm, and binds and stabilizes the methyltransferase PRMT5 by preventing the association of PRMT5 to the E3 ubiquitin ligase CHIP.

    • Zhe Li
    • , Jiwei Zhang
    •  & Xianghuo He

  • Article
    | Open Access

    Gain-of-function mutants of p53 are important for cancer development and strategies to target specifically these isoforms are being investigated. Here the authors report that USP15 is a deubiquitinase specifically regulating p53-R175H levels that can be targeted by a small molecule.

    • Achuth Padmanabhan
    • , Nicholes Candelaria
    •  & JoAnne S. Richards

  • Article
    | Open Access

    Although we know lncRNAs play a role in cancer, the identification of clinically relevant and functional lncRNAs is lacking. Here, the authors identify 633 prognostic markers, 570 S-phase cancer-associated lncRNAs, and show SCAT7 regulates FGF/FGFR and PI3K/AKT/MAPK pathways via interaction with hnRNPK/YBX1 complexes.

    • Mohamad Moustafa Ali
    • , Vijay Suresh Akhade
    •  & Chandrasekhar Kanduri

  • Article
    | Open Access

    Chordoid glioma is a rare low-grade brain tumor that originates from the anterior wall of the third ventricle where surgical resection is challenging; the clinical outcome of patients after subtotal resection or disease recurrence is poor. Here the authors identify a recurrent missense mutation in PRKCA that may serve as a potential therapeutic target in this uncommon brain cancer.

    • Benjamin Goode
    • , Gourish Mondal
    •  & David A. Solomon

  • Article
    | Open Access

    The mechanism of tumor progression robustly promoted by co-existing BRAF V600E and TERT promoter mutations is not known. Here, the authors show a mechanism of mutant TERT activation by BRAF V600E and MAPK pathways in which FOS, as a transcription factor of the GABPB promoter, functionally links the two oncogenes.

    • Rengyun Liu
    • , Tao Zhang
    •  & Mingzhao Xing

  • Article
    | Open Access

    Genome editing technologies enable the rapid interrogation of genetic alterations. Here, the authors present a CRISPR/Cas9-based platform to simultaneously investigate multiple activating point mutations in de novo cancers in mice; and generate panels of Kras-variants in different tissues to induce cancer.

    • Ian P. Winters
    • , Shin-Heng Chiou
    •  & Monte M. Winslow

  • Article
    | Open Access

    Activated PI3K causes cancer, but the role of active PI3K mutations in early stages of malignancy are unclear. Here, the authors show in a mouse model that active PI3K induces centrosome amplification via AKT, ROCK, CDK2/Cyclin E and nucleophosmin, and increased tolerance of genome doubling.

    • Inma M. Berenjeno
    • , Roberto Piñeiro
    •  & Bart Vanhaesebroeck

  • Article
    | Open Access

    Notch receptors can exert different roles in cancer. In this manuscript, the authors reveal that Notch1 activation and EMT promote tumor initiation and cancer cell heterogeneity in squamous cell carcinoma, while the repression of Notch3 by ZEB1 limits Notch1-induced differentiation, permitting Notch1-mediated EMT.

    • Mitsuteru Natsuizaka
    • , Kelly A. Whelan
    •  & Hiroshi Nakagawa

  • Article
    | Open Access

    BCL-XL provides a survival advantage to cancer cells even in the absence of apoptotic pressures. In this study, the authors show that BCL-XL interacts with RAS in a BH4-dependent manner and regulates RAS-mediated activation of pathways involved in the stemness feature of breast cancer cells.

    • Sophie de Carné Trécesson
    • , Frédérique Souazé
    •  & Philippe Paul Juin

  • Article
    | Open Access

    Pancreatic cancer cells may develop resistance to KRAS inhibitors due to activation of compensatory pathways. In this study, the authors demonstrate that KRAS is dispensable in a subset of pancreatic cancer and that PI3K signalling may have an important role in mediating tumor growth following KRAS inhibition.

    • Mandar Deepak Muzumdar
    • , Pan-Yu Chen
    •  & Tyler Jacks

  • Article
    | Open Access

    Several rearrangements of the MLL gene are associated with acute leukemia, including the fusion of MLL with a RAS effector protein, AF6. Here the authors show that the truncated AF6 can induce AF6-MLL dimerization and drive its oncogenic activity.

    • Matthew J. Smith
    • , Elizabeth Ottoni
    •  & Mitsuhiko Ikura

  • Article
    | Open Access

    Cancer cells adapt to the changing microenvironment by activating different pathways through multiple mechanisms. Here the authors identify long noncoding RNAMIR31HGas a HIF-1α co-activator required for the induction of the hypoxic response and show its oncogenic role in oral carcinogenesis.

    • Jing-Wen Shih
    • , Wei-Fan Chiang
    •  & Hsing-Jien Kung

  • Article
    | Open Access

    KRAS mutations drive resistance to diverse targeted therapies. In this study, the authors show that the rare codons of KRAS, yielding low oncogene expression, can be overcome to drive resistance to anti-EGFR therapy in CRC through upregulation of global translation or through selection of more potent KRASQ61mutations.

    • Moiez Ali
    • , Erin Kaltenbrun
    •  & Kris C. Wood

Browse broader subjects

Browse Oncogenes across other nature.com journals